Select News

Mar 18 2015

Esperion Therapeutics Prices Public Offering of Common Stock

Mar 18 2015

ANN ARBOR, MI — (Marketwired) — 03/19/15 — Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced the pricing of an underwritten public offering of 1,750,000 shares of its common stock, offered at a price to the public of $100.00 per share. The gross proceeds from this offering to Esperion are expected to be $175 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Esperion. Esperion has granted the underwriters a 30-day option to purchase up to an additional 262,500 shares of its common stock. The offering is expected to close on or about March 24, 2015, subject to customary closing conditions. Esperion intends to use the net proceeds from the offering, as well as its other existing capital resources, to complete the clinical development of ETC-1002, including development of a fixed-dose combination of ETC-1002 and ezetimibe for statin intolerant patients, pre-commercial launch activities for ETC-1002 in the statin intolerant patient population, the initiation of a cardiovascular outcomes trial for high-risk patients who have had a cardiovascular event, working capital, and for general corporate and administrative expenses.

READ MORE

Mar 17 2015

Esperion Therapeutics Announces Positive Top-Line Phase 2b Results for ETC-1002 Added to Stable Statin Therapy in Patients With Hypercholesterolemia

Mar 17 2015

ANN ARBOR, MI — (Marketwired) — 03/17/15 — Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers, today announced positive top-line results from ETC-1002-009, a Phase 2b study evaluating the efficacy and safety of ETC-1002 (bempedoic acid) compared with placebo in patients with hypercholesterolemia on stable statin therapy.

READ MORE

Mar 12 2015

Allergen Research Corporation Completes $80 Million Series B Financing to Advance Drug Development Portfolio for Food Allergy

Mar 12 2015

SAN MATEO, Calif., March 12, 2015— Allergen Research Corporation (ARC), a privately held biopharmaceutical company developing desensitization treatments for food allergies, today announced the completion of an $80 million Series B financing. Foresite Capital led the round, with participation from existing investor Longitude Capital and new investors Fidelity Management & Research Company, Aisling Capital, Adage Capital, RA Capital Management and Palo Alto Investors.

READ MORE

Mar 10 2015

Pernix to Acquire Zohydro® ER Franchise from Zogenix, Inc.

Mar 10 2015

MORRISTOWN, NJ – (BUSINESS WIRE) – March 10, 2015 – Pernix Ireland Limited, a wholly owned subsidiary of Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, announced today that it has signed a definitive agreement to acquire the Zohydro ER franchise from Zogenix, Inc. (NASDAQ: ZGNX). The acquisition includes three extended release hydrocodone products, including an abuse-deterrent pipeline and all related intellectual property. Pernix has agreed to pay $100 million at closing, plus regulatory and commercial milestones of up to $283.5 million if the Zohydro ER franchise achieves agreed-upon net sales targets of up to $1 billion annually.

READ MORE

Feb 26 2015

Intersect ENT Reports Fourth Quarter and Year 2014 Results

Feb 26 2015

MENLO PARK, Calif.–(BUSINESS WIRE)– Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the fourth quarter and year ended December 31, 2014.

2014 Business Highlights

  • Achieved year over year revenue growth of 115%
  • Realized 2014 gross margin of 74% versus 55% in 2013
  • Completed the RESOLVE study and commenced the RESOLVE II study in December 2014. RESOLVE II is a pivotal Phase III clinical study of the company’s RESOLVE steroid releasing implant designed to treat patients with recurrent sinus obstruction in the office setting
  • Commenced enrollment in September 2014 of the PROGRESS study to assess the safety and efficacy of the PROPEL® mini steroid releasing sinus implant when placed in the frontal sinus opening
  • Completed enrollment in a feasibility study to assess the company’s investigational NOVA steroid releasing sinus implant. This implant is designed primarily as a treatment in the physician’s office for patients suffering from chronic sinusitis who have not yet had sinus surgery
  • Completed an initial public offering in July 2014, raising net proceeds of $55.8 million, after deducting underwriting discounts and commissions and offering expenses
READ MORE

Feb 23 2015

ADMA Biologics Announces Positive Data on Primary and Secondary Endpoints from its Pivotal Phase III Clinical Trial for RI-002 at the AAAAI Medical Conference

Feb 23 2015

RAMSEY, N.J., Feb. 23, 2015 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, announced positive results on the primary and secondary endpoint evaluations from its pivotal Phase III trial for RI-002 in Primary Immune Deficiency Disease (PIDD) in a poster presentation yesterday at the American Academy of Allergy, Asthma and Immunology Annual Meeting (http://annualmeeting.aaaai.org). In December 2014, the company announced that the trial met its primary endpoint with zero serious bacterial infections (SBI).

READ MORE

Feb 6 2015

Dermira Announces Positive Phase 2b Results for DRM04 in Patients with Hyperhidrosis

Feb 6 2015

MENLO PARK, Calif., February 5, 2015 – Dermira, Inc. (NASDAQ: DERM), a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients, today announced positive Phase 2b study results for DRM04, its proprietary topical anticholinergic product, in patients with axillary hyperhidrosis, or excessive underarm sweating. Based on the results of this study (DRM04-HH02) and its first Phase 2b study (DRM04-HH01), Dermira plans to initiate a Phase 3 program for DRM04 in axillary hyperhidrosis in the second half of 2015, consistent with previous expectations and subject to an end-of-phase 2 meeting with the U.S. Food and Drug Administration (FDA).

READ MORE

Feb 2 2015

Esperion Therapeutics Announces Removal of PPAR Partial Clinical Hold for ETC-1002

Feb 2 2015

ANN ARBOR, MI –(Marketwired – February 02, 2015) – Esperion Therapeutics, Inc. (NASDAQ: ESPR), an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of hypercholesterolemia and other cardio-metabolic risk markers, today announced the U.S. Food and Drug Administration (FDA) has removed the peroxisome proliferator-activated receptor (PPAR) partial clinical hold on ETC-1002. The action by the FDA will now allow Esperion to conduct clinical trials exceeding six months in duration.

READ MORE

Jan 4 2015

Cempra Announces Positive Topline Phase 3 Clinical Results for Oral Solithromycin in the Treatment of Community Acquired Bacterial Pneumonia

Jan 4 2015

CHAPEL HILL, N.C., Jan. 4, 2015 (GLOBE NEWSWIRE) — Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics in the face of rising antibiotic resistant bacterial infections, today announced positive topline results from a global, pivotal Phase 3 clinical trial of solithromycin oral capsules (Solitaire- Oral) in the treatment of patients with community acquired bacterial pneumonia (CABP).

READ MORE

Dec 3 2014

ADMA Biologics Announces Positive Top-Line Phase III Data for Primary Immune Deficiency Disease (PIDD) Patients

Dec 3 2014

RAMSEY, N.J., Dec. 3, 2014 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced its lead product candidate RI-002 has demonstrated positive Phase III results and successfully achieved its primary endpoint.

READ MORE